A5090576464- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Genetic factors in colorectal cancer
- Advanced Breast Cancer Therapies
- BRCA gene mutations in cancer
- Monoclonal and Polyclonal Antibodies Research
- Radiopharmaceutical Chemistry and Applications
- Cancer Immunotherapy and Biomarkers
- Cancer, Hypoxia, and Metabolism
- Chronic Lymphocytic Leukemia Research
- Advanced Radiotherapy Techniques
- Estrogen and related hormone effects
- Radiomics and Machine Learning in Medical Imaging
- Molecular Biology Techniques and Applications
- Breast Lesions and Carcinomas
- DNA Repair Mechanisms
- Pancreatic and Hepatic Oncology Research
- Plant Virus Research Studies
- Lung Cancer Treatments and Mutations
- Histone Deacetylase Inhibitors Research
- Prostate Cancer Treatment and Research
- Polyomavirus and related diseases
Natera (United States)
2020-2025
Commonwealth Medical College
2024
University of Arkansas for Medical Sciences
2023
University of Arkansas at Little Rock
2023
Houston Methodist
2013-2022
Methodist Hospital
2012-2021
Cornell University
2011-2021
Weill Cornell Medicine
2016-2021
Hospital Universitario Miguel Servet
2008-2020
Guardant (United States)
2016-2018
Some breast cancers have been shown to contain a small fraction of cells characterized by CD44(+)/CD24(-/low) cell-surface antigen profile that high tumor-initiating potential. In addition, cancer propagated in vitro as mammospheres (MSs) also be enriched for capable self-renewal. this study, we defined gene expression signature common both and MS-forming cells. To examine its clinical significance, determined whether tumor surviving after conventional treatments were bearing...
We previously reported the eradication of human epidermal growth factor receptor 2 (HER2)- amplified xenografts in mice by inhibition HER2 pathway with lapatinib and trastuzumab to block all homo- heterodimer signaling as well blockade estrogen (ER) when expressed. In this clinical trial, we sought translate these findings patients using targeted therapy without chemotherapy.Women stages II III HER2-positive breast cancers were eligible. They received once per week (4 mg/kg loading, then...
Triple-negative breast cancer (TNBC) is an aggressive form of with no effective targeted therapy. Inducible nitric oxide synthase (iNOS) associated poor survival in patients by increasing tumor aggressiveness. This work aimed to investigate the potential iNOS inhibitors as a therapy for TNBC. We hypothesized that inhibition endogenous would decrease TNBC aggressiveness reducing initiation and metastasis through modulation epithelial-mesenchymal transition (EMT)-inducing factors.iNOS protein...
Circulating tumor DNA (ctDNA) analysis may improve early-stage breast cancer treatment via non-invasive burden assessment. To investigate subtype-specific differences in the clinical significance and biology of ctDNA shedding, we perform serial personalized hormone receptor (HR)-positive/HER2-negative triple-negative (TNBC) patients receiving neoadjuvant chemotherapy (NAC) I-SPY2 trial. positivity rates before, during, after NAC are higher TNBC than HR-positive/HER2-negative patients. Early...
Patients with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant chemotherapy generally have worse outcome; however, some patients tumor do not relapse. We hypothesize that there are subgroups of chemoresistant TNBC different prognosis.Forty-nine cases from 111 treated (M.D. Anderson Cancer Center, Houston, TX) constituted the discovery cohort, 25 samples 47 chemotherapy-treated (The Methodist Hospital, were chosen for validation. Extended validation was carried out...
Abstract Triple negative breast cancer (TNBC) is known to contain a high percentage of CD44+/CD24−/low stem cells (CSCs), corresponding with poor prognosis despite systemic chemotherapy. Chloroquine (CQ), an antimalarial drug, lysotropic reagent which inhibits autophagy. CQ was identified as potential CSC inhibitor through in silico gene expression signature analysis the population. Autophagy plays critical role adaptation stress conditions cells, and related drug resistance maintenance....
Purpose To determine the potential for detection of incidental germline cancer predisposition mutations through cell-free DNA (cfDNA) analyses in patients who underwent solid tumor somatic mutation evaluation. Patients and Methods Data were evaluated from 10,888 unselected with advanced (stage III/IV) Guardant360 testing between November 2015 December 2016. The main outcome was prevalence putative identified among 16 actionable hereditary genes. Results More than 50 types studied, including...
A phase 1/2 clinical trial in patients with chemoresistant triple-negative breast cancer targets the inducible nitric oxide signaling pathway.
PURPOSE Here, we report the sensitivity of a personalized, tumor-informed circulating tumor DNA (ctDNA) assay (Signatera) for detection molecular relapse during long-term follow-up patients with breast cancer. METHODS A total 156 primary cancer were monitored clinically up to 12 years after surgery and adjuvant chemotherapy. Semiannual blood samples prospectively collected, analyzed retrospectively detect residual disease by ultradeep sequencing using ctDNA assays, developed from whole-exome...
We hypothesized that the Oncotype Dx® 21-gene Recurrence Score (RS) could guide neoadjuvant systemic therapy (NST) to facilitate breast conserving surgery (BCS) for hormone receptor positive (HR+) cancers.This study enrolled patients with HR+, HER2-negative, invasive cancers not suitable BCS (size ≥ 2 cm). Core needle biopsy blocks were tested. For tumors RS < 11, received hormonal (NHT); > 25 chemotherapy (NCT); 11-25 randomized NHT or NCT. Primary endpoint was whether 1/3 more of refused...
Invasive micropapillary carcinoma (IMPC) is a variant of breast with higher propensity for lymph node metastases compared invasive ductal (IDC). Retrospective analysis 636 IMPC and 297 735 IDC cases in the Surveillance, Epidemiology End Results database comparing disease-specific survival (DSS) overall (OS) between IDC. A percentage (52.0%) had nodal (34.6%). The 5-year DSS OS was 91.8% 82.9%, respectively 88.6% 80.5% IDC, respectively. For both oestrogen-receptor positivity associated...
BACKGROUND A key challenge to mining electronic health records for mammography research is the preponderance of unstructured narrative text, which strikingly limits usable output. The imaging characteristics breast cancer subtypes have been described previously, but without standardization parameters data mining. METHODS authors searched enterprise‐wide warehouse at Houston Methodist Hospital, Environment Translational Enhancement and Outcomes Research (METEOR), patients with Breast Imaging...
Abstract Background Triple negative breast cancer (TNBC) is an aggressive subtype with poor prognosis. We aimed to determine whether circulating tumor DNA (ctDNA) and cell (CTC) could predict response long-term outcomes neoadjuvant chemotherapy (NAC). Methods Patients TNBC were enrolled between 2017–2021 at The University of Texas MD Anderson Cancer Center (Houston, TX). Serial plasma samples collected four timepoints: pre-NAC (baseline), 12-weeks after NAC (mid-NAC), NAC/prior surgery...
Abstract Background Since the first suggestion of prospectively identifiable cancer stem cells in solid tumors, efforts have been made to characterize reported cell surrogates existing lines, and lines rich with these used screen for targeted agents. Although 293T were derived from human embryonic kidney, transplantation into mammary fat pad yields aggressive tumors that self-renew as evidenced by serial xenograft passages through transplantation. Herein we fully cell-like features kidney...
Developing novel strategies against treatment-resistant triple negative breast cancer (TNBC) cells remains a significant challenge. The ErbB family, including epidermal growth factor receptor (EGFR), plays key roles in metastasis, tumorigenesis, cell proliferation, and drug resistance. Recently, these characteristics have been linked to small subpopulation of classified as stem (CSC) which are believed be responsible for tumor initiation maintenance. Ixabepilone is new generation...
Neoadjuvant dual human epidermal growth factor receptor (HER2) blockade with trastuzumab and pertuzumab plus paclitaxel leads to an overall pathologic complete response (pCR) rate of 46%. Dual HER2 ado-trastuzumab emtansine (T-DM1) lapatinib nab-paclitaxel has shown efficacy in patients metastatic HER2-positive breast cancer. To test neoadjuvant effectiveness this regimen, open-label, multicenter, randomized, phase II trial was conducted comparing T-DM1, lapatinib, trastuzumab, pertuzumab,...
Abstract Background: ctDNA monitoring during adjuvant endocrine therapy provides an opportunity to detect molecular relapse before clinically apparent recurrence. The rate and dynamics of positivity the frequency asymptomatic but imaging detectable metastatic disease at time detection remain unknown in high-risk ER+/HER2- breast cancers. We present results rates 508 ctDNA+ patients from a prospective, multicenter, randomized surveillance intervention trial, DARE (NCT04567420). Patients...
Introduction Colorectal cancer (CRC) is a highly prevalent disease, wherein, ~30%–40% of patients with CRC relapse postresection. In some CRC, adjuvant chemotherapy can help delay recurrence or be curative. However, current biomarkers show limited clinical utility in determining if/when should administered, to provide benefit. Circulating tumour DNA (ctDNA) measure molecular residual disease (MRD) and high specificity sensitivity. This study protocol investigates the ctDNA for optimal use...
Merkel cell carcinoma (MCC) is an aggressive skin cancer with a 40% recurrence rate, lacking effective prognostic biomarkers and surveillance methods. This prospective, multicenter, observational study aimed to evaluate circulating tumor DNA (ctDNA) as biomarker for detecting MCC recurrence.